KalVista Pharmaceuticals, Inc. (KALV)

-3.44% (1D)

Market Cap	600.07M
Revenue (ttm)	n/a
Net Income (ttm)	-175.87M
Shares Out	49.72M
EPS (ttm)	-3.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	496,127
Open	12.32
Previous Close	12.50
Day's Range	11.96 - 12.43
52-Week Range	7.30 - 15.50
Beta	0.76
Analysts	Strong Buy
Price Target	24.83 (+105.72%)
Earnings Date	Mar 12, 2025

About KALV

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID f...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Benjamin Palleiko
• Employees: 150
• Stock Exchange: NASDAQ
• Ticker Symbol: KALV
• Website: https://www.kalvista.com

Analyst Forecast

According to 8 analysts, the average rating for KALV stock is "Strong Buy." The 12-month stock price forecast is $24.83, which is an increase of 105.72% from the latest price.

Price Target

$24.83

(105.72% upside)

Analyst Consensus: Strong Buy